Entasis Therapeutics Holdings Inc. (ETTX) News
Filter ETTX News Items
ETTX News Results
|Loading, please wait...|
Latest ETTX News From Around the Web
Below are the latest news stories about ENTASIS THERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate ETTX as an investment opportunity.
Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference
WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the American Society for Microbiology (ASM) annual Microbe conference, taking place June 9-13, 2022, in Washington, DC. Entasis is presenting data on sulbactam-durlobactam (SUL-DUR), an investigational drug in development for the treat
Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
ENTASIS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of ETTX and Encourages Investors to Contact the Firm
NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Innoviva, Inc. (NASDAQ: INVA).
Innoviva (INVA) is set to acquire Entasis (ETTX) for $2.20 per share in cash. The transaction is likely to close by third-quarter 2022.
Entasis Therapeutics, an antibiotics developer that spun out of AstraZeneca plc in 2015, has been acquired by its majority shareholder, California's Innoviva Inc.
Innoviva (INVA) and Entasis Therapeutics Holdings (ETTX) has entered into a definitive merger agreement under which Innoviva is to acquire all of the outstanding shares of Entasis at…
Innoviva Inc (NASDAQ: INVA ) has agreed to acquire Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) at $2.20 per share in cash. Innoviva currently owns approximately 60% of the outstanding shares of Entasis common stock. The acquisition consideration values Entasis'' equity at $113 million on a fully diluted basis. "This acquisition will build upon our overall strategy to acquire … Full story available on Benzinga.com
GeoVax Labs GOVX +39%. Entasis Therapeutics ETTX +21%. Nymox Pharmaceutical NYMX -67%. Evoke Pharma EVOK -21%.
BURLINGAME, Calif. & WALTHAM, Mass., May 23, 2022--Innoviva, Inc. (Nasdaq: INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) ("Entasis"), an advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the companies have entered into a definitive merger agreement under which
Kevin Outterson has spent the better part of the last year in conversations with CARB-X's previous backers. Now, those efforts have yielded fruit: The organization has another $370 million to invest in research targeting drug-resistant bacteria.